The Alteration of Aspart Insulin Pharmacodynamics Wh

Diabetes Care

35, 690-692

DOI: 10.2337/dc11-0732

Citation Report

#	Article	IF	Citations
1	Undeniable Need for Ultrafast-Acting Insulin: The Pediatric Perspective. Journal of Diabetes Science and Technology, 2012, 6, 797-801.	2.2	28
2	Management of Diabetic Cats with Long-acting Insulin. Veterinary Clinics of North America - Small Animal Practice, 2013, 43, 251-266.	1.5	14
3	Management of Pediatric Patients with Type 1 Diabetes. Pediatric Annals, 2014, 43, 115-120.	0.8	3
5	Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Therapy, 2014, 5, 255-265.	2.5	61
6	Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial. Pediatric Diabetes, 2015, 16, 345-353.	2.9	5
7	Insulin degludec/insulin aspart produces a doseâ€proportional glucoseâ€lowering effect in subjects with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2015, 17, 659-664.	4.4	20
8	Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Therapeutic Advances in Chronic Disease, 2015, 6, 375-388.	2.5	23
9	Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart. Pharmaceutical Research, 2015, 32, 2250-2258.	3.5	38
11	IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. Expert Review of Endocrinology and Metabolism, 2016, 11, 103-111.	2.4	4
12	Clinical use of the co-formulation of insulin degludec and insulin aspart. International Journal of Clinical Practice, 2016, 70, 657-667.	1.7	14
13	Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucoseâ€lowering effects. Journal of Diabetes Investigation, 2016, 7, 574-580.	2.4	8
14	The past, present, and future of basal insulins. Diabetes/Metabolism Research and Reviews, 2016, 32, 478-496.	4.0	63
15	Moving toward the ideal insulin for insulin pumps. Expert Review of Medical Devices, 2016, 13, 57-69.	2.8	30
16	Efficacy and safety of onceâ€daily insulin degludec/insulin aspart compared with onceâ€daily insulin glargine in participants with Type 2 diabetes: a randomized, treatâ€toâ€target study. Diabetic Medicine, 2017, 34, 180-188.	2.3	34
17	Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulinâ€experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Panâ€Asian, treatâ€toâ€target Phase 3 Trial. Journal of Diabetes, 2017, 9, 243-247.	1.8	11
18	Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basalâ€“bolus treatment in people with Type 1 diabetes: 1â€“year results from a randomized clinical trial (<scp>BOOST</scp>^{Â®} T1). Diabetic Medicine, 2017, 34, 167-173.	2.3	32
19	A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clinical Pharmacokinetics, 2017, 56, 339-354.	3.5	30
20	Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients. Expert Opinion on Biological Therapy, 2018, 18, 77-85.	3.1	0

#	Article	IF	Citations
21	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes, 2018, 19, 115-135.	2.9	164
22	It is possible to mix insulins in the same syringe?. Revista Clínica Espanõla, 2019, 219, 226-227.	0.5	0
23	Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 1961-1975.	4.4	11
24	Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience. Archives of Medical Science, 2021, 17, 1-8.	0.9	11
25	Insulin Treatment of Type 1 Diabetes. Contemporary Endocrinology, 2021, , 43-53.	0.1	0
27	When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice, 2016, 22, 12-14.	2.1	0
28	When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice, 2016, 22, 14-22.	2.1	0
29	When and how to Use Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice, 2016, 22, 9-12.	2.1	0
30	Â¿Es posible mezclar insulinas en una misma jeringa?. Revista Clinica Espanola, 2019, 219, 226-227.	0.6	0
31	ISPAD Clinical Practice Consensus Guidelines 2018. Chapter 9. Insulin treatment in children and adolescents with diabetes. Ukrainian Journal of Pediatric Endocrinology, 2020, .	0.1	0
32	Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons. Current Issues in Molecular Biology, 2022, 44, 867-888.	2.4	2